Symphony Capital Report issue

For profit Phase 2
Founded: New York NY United States (2002)
Status: Defunct (2016)

Organization Overview

First Clinical Trial
2002
NCT00209508
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Alternative names

Symphony Evolution, Inc. | Symphony Genisis | Symphony Health Solutions | Symphony Vida

Active Ingredients

Drugs in Phase 2 Trials (3)

gpi 1485 (2 trials)

xl784 (1 trial)

xl999 (9 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Albuminuria (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Colorectal Neoplasms (Phase 2)

Diabetic Nephropathies (Phase 2)

Erectile Dysfunction (Phase 2)

Kidney Diseases (Phase 2)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lung Neoplasms (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasms (Phase 1)

Neoplasms, Plasma Cell (Phase 2)

Ovarian Neoplasms (Phase 2)

Parkinson Disease (Phase 2)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 12
  • # of Trial APIs: 3